Bisoprolol in DMD Early Cardiomyopathy

Status Recruiting

Clinical Trial Summary

This study aimed to use cardiac magnetic resonance imaging (CMR) to evaluate the efficacy and safety of bisoprolol therapy for boys with Duchenne muscular dystrophy(DMD) and preserved ejection fraction. On top of angiotensin-converting enzyme inhibitor (ACEI) , half of the participants will receive bisoprolol in combination, while the other half will not receive any beta-blocker.

Clinical Trial Description

By the age of 20 years, almost all the patients with Duchenne muscular dystrophy(DMD) have experienced dilated cardiomyopathy (DCM), a condition that contributes significantly to their morbidity and mortality. Studies have shown ACEI to be an effective therapy for DMD boys with early cardiomyopathy. Although bisoprolol has been demonstrated as an effective neurohumoral drug for adult patients with DCM, few data exist concerning its safety and efficacy for the patients with DMD. The investigators hypothesize that the treatment with bisoprolol in addition to background ACEI therapy for 12 months in participants with DMD and early myocardial damage evident with late gadolinium enhancement and preserved ejection fraction, would blunt decline in left ventricular systolic performance. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT03779646
Study type	Interventional
Source	Peking Union Medical College Hospital
Contact	Guo, Doctor
Phone	+86-010-69155068
Email	xiaoxiaoguopumch@163.com
Status	Recruiting
Phase	Phase 2/Phase 3
Start date	January 16, 2019
Completion date	July 1, 2024

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT05575648` - Dual Task in Duchenne Muscular Dystrophy	N/A
Terminated	`NCT03907072` - Efficacy and Safety Study of WVE-210201 (Suvodirsen) With Open-label Extension in Ambulatory Patients With Duchenne Muscular Dystrophy	Phase 2/Phase 3
Not yet recruiting	`NCT06450639` - An Open-label Study to Assess the Efficacy and Safety of Satralizumab in Duchenne Muscular Dystrophy	Phase 2
Completed	`NCT04335942` - Characterization of the Postural Habits of Wheelchair Users Analysis of the Acceptability of International Recommendations in the Prevention of Pressure Sores Risk by Using a Connected Textile Sensor	N/A
Active, not recruiting	`NCT04906460` - Open-label Study of WVE-N531 in Patients With Duchenne Muscular Dystrophy (FORWARD-53)	Phase 1/Phase 2
Active, not recruiting	`NCT02500381` - Study of SRP-4045 (Casimersen) and SRP-4053 (Golodirsen) in Participants With Duchenne Muscular Dystrophy (DMD)	Phase 3
Enrolling by invitation	`NCT05967351` - A Long-term Follow-up Study of Participants Who Received Delandistrogene Moxeparvovec (SRP-9001) in a Previous Clinical Study	Phase 3
Recruiting	`NCT03067831` - Bone Marrow-Derived Autologous Stem Cells for the Treatment of Duchenne Muscular Dystrophy	Phase 1/Phase 2
Recruiting	`NCT01834040` - Study Safety and Efficacy of BMMNC for the Patient With Duchenne Muscular Dystrophy	Phase 1/Phase 2
Completed	`NCT02246478` - A Study of TAS-205 for Duchenne Muscular Dystrophy	Phase 1
Active, not recruiting	`NCT01772043` - Duchenne Muscular Dystrophy Tissue Bank for Exon Skipping	N/A
Terminated	`NCT01168908` - Revatio for Heart Disease in Duchenne Muscular Dystrophy and Becker Muscular Dystrophy	Phase 2
Completed	`NCT00758225` - Long-term Safety, Tolerability and Efficacy of Idebenone in Duchenne Muscular Dystrophy (DELPHI Extension)	Phase 2
Completed	`NCT03680365` - Your Voice; Impact of Duchenne Muscular Dystrophy (DMD) on the Lives of Families
Recruiting	`NCT03513367` - The Validation Process for Confirmation of the French Version of the Pediatric Quality of Life Inventory :PedsQLTM.
Recruiting	`NCT05712447` - Duchenne Muscular Dystrophy Video Assessment Registry
Recruiting	`NCT01484678` - Magnetic Resonance Imaging and Biomarkers for Muscular Dystrophy
Completed	`NCT03319030` - Aerobic Exercise in Boys With Duchenne Muscular Dystrophy (DMD)
Terminated	`NCT01753804` - A Prospective Natural History Study of Progression of Subjects With Duchenne Muscular Dystrophy.	N/A
Completed	`NCT02530905` - Dose-Titration and Open-label Extension Study of SRP-4045 in Advanced Stage Duchenne Muscular Dystrophy (DMD) Patients	Phase 1